Moderna says flu shot misses early success bar, but expects 2024 revenue ...Middle East

Devdiscourse - Opinion
Moderna says flu shot misses early success bar, but expects 2024 revenue
Moderna Inc said on Tuesday its experimental flu vaccine did not meet the criteria for "early success" in a late-stage trial, and its shares fell 3%. The U.S. biotech company at its vaccine day meeting in Boston also said it expects to have six major vaccines on the market in the next few years. Its COVID-19 shot is currently the company's lone marketed product.

Hence then, the article about moderna says flu shot misses early success bar but expects 2024 revenue was published today ( ) and is available on Devdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Moderna says flu shot misses early success bar, but expects 2024 revenue )

Apple Storegoogle play

Last updated :

Also on site :



Latest News